| Trial ID: | L6233 |
| Source ID: | NCT00291356
|
| Associated Drug: |
Gsk189075 Oral Tablets
|
| Title: |
GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2|Non-Insulin-Dependent Diabetes Mellitus
|
| Interventions: |
DRUG: GSK189075 oral tablets|DRUG: GW869682 oral tablets
|
| Outcome Measures: |
Primary: Safety and tolerability: side effects and relevant changes in blood pressure, heart rate and ECG measurements, blood and urine measurements, the amount of fluid taken in and excreted, and kidney function will be monitored over course of study. | Secondary: Amount and percentage of glucose excreted in urine by kidneys. Effect of compounds on lipid metabolism analysed.
|
| Sponsor/Collaborators: |
Sponsor: GlaxoSmithKline
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
45
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: DOUBLE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-01
|
| Completion Date: |
2006-05
|
| Results First Posted: |
|
| Last Update Posted: |
2015-04-15
|
| Locations: |
GSK Investigational Site, Chula Vista, California, 91910, United States|GSK Investigational Site, Neuss, Nordrhein-Westfalen, 41460, Germany|GSK Investigational Site, Berlin, 14050, Germany
|
| URL: |
https://clinicaltrials.gov/show/NCT00291356
|
